Acquire the license to the best health content in the world
Contact Us

Lapatinib Minimally Effective Against Liver Cancer

Study suggests drug may stabilize disease, but does not reduce disease progression

THURSDAY, Sept. 10 (HealthDay News) -- Lapatinib is not effective in reducing disease progression in patients with advanced liver cancer, according to a study published online Sept. 8 in Clinical Cancer Research.

As part of an open-label Phase II trial, Tanios Bekaii-Saab, M.D., from Ohio State University in Columbus, and colleagues treated 26 patients with hepatocellular carcinoma with 1,500 mg daily oral lapatinib on 28-day cycles.

The researchers found that none of the patients had an objective response. Stable disease was present in 40 percent of patients, which lasted more than 120 days in 23 percent of all patients. The median progression-free survival was 1.9 months, while the median overall survival was 12.6 months, although median overall survival was significantly longer in the 42 percent of patients who developed a rash (16.2 months compared with 8.7 months for patients without a rash). The authors further note that there were no somatic mutations in EGFR or HER2/NEU, the targets of lapatinib. The expression of several downstream signaling proteins also did not correlate with survival.

"Lapatinib is well-tolerated but seems to benefit only a subgroup of patients for whom predictive molecular or clinical characteristics are not yet fully defined," Bekaii-Saab and colleagues conclude.

Bekaii-Saab reported a financial and consulting relationship with Genentech.

Full Text (subscription or payment may be required)

Physician's Briefing